Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Antibody‐dependent complement activity is associated not only with autoimmune morbidity,
but also with antitumor efficacy. In infectious disease, both recombinant monoclonal …

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …

Developing efficacious vaccines for human malaria caused by Plasmodium falciparum is a
major global health priority, although this has proven to be immensely challenging over the …

CD4+ T follicular helper cells (Tfh) are key drivers of antibody development. During
Plasmodium falciparum malaria in children, the activation of Tfh is restricted to the Th1 …

Background As malaria transmission declines, sensitive diagnostics are needed to evaluate
interventions and monitor transmission. Serological assays measuring malaria antibody …

The malaria parasite has for long been thought to escape host complement attack as a
survival strategy. However, it was only recently that complement evasion mechanisms of the …

Development of a successful blood-stage vaccine against Plasmodium falciparum malaria
remains a high priority. Immune-epidemiological studies are effective tools for the …

The interactions between Plasmodium parasites and human erythrocytes are prime targets
of blood stage malaria vaccine development. The reticulocyte binding protein 2-P1 (RBP2 …

Malaria continues to impact on young lives, causing sickness, impaired school performance,
disability, and preventable death, with little progress made to reduce the overall burden …